Immune Checkpoint Inhibitor Use Near the End of Life Is Associated With Poor Performance Status, Lower Hospice Enrollment, and Dying in the Hospital.
Chad GlischYuya HagiwaraStephanie Gilbertson-WhiteYubo GaoLaurel LyckholmPublished in: The American journal of hospice & palliative care (2019)
Immune checkpoint inhibitor use in the last 30 days of life is common and associated with poor performance status, lower hospice enrollment, and dying in the hospital.